BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Culinary Joys: Investigating Connoisseur Cooking at Home01.01.1 - 2Flash flooding causes highways to close to and from Eilat06.12.2025
- 35 Arising Professions in Environmentally friendly power01.01.1
- 4Manual for Tracking down the Mysterious Cascades in China01.01.1
- 5The Significance of Prenuptial Arrangements in Separation Procedures30.06.2023
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- The Most Paramount Crossroads in Olympic History
- Manual for extravagance SUVs for seniors
- Building a Maintainable Closet: Individual Excursions in Moral Style
- The Craft of Computerized Detox: Individual Trials
- Instructions to Keep up with Your Traded Teeth for Life span
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 5 things for parents to know about changes to kids vaccine schedule
- 75% of US adults may meet criteria for obesity under new definition, study finds
